Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

NRXP
NRX Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Market Open
Sep 17, 2025 3:51:28 PM EDT
2.94USD-1.342%(-0.04)318,115
2.91Bid   2.96Ask   0.05Spread
Pre-market
Sep 17, 2025 8:19:30 AM EDT
3.00USD+0.671%(+0.02)4,576
After-hours
Sep 16, 2025 4:35:30 PM EDT
3.03USD+3.061%(+0.09)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
06:54PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
02:37PM EST  Mid-Afternoon Market Update: Nasdaq Jumps 375 Points; Imperial Petroleum Shares Drop   Benzinga
08:00AM EST  NRx Pharma Announces $25 Mln Private Placement Priced At Premium To Market   RTTNews
07:59AM EST  NRx Pharmaceuticals Announces $25M Private Placement Priced At A Premium To Market Under Nasdaq Rules   Benzinga
07:59AM EST  NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium   PR Newswire
Jan 27, 2022
06:57AM EST  NRx Announces Publication of Initial Findings of BriLife Vaccine-produced Antibodies Against Omicron Variant; Said Neutralizing Antibody Level Against Omicron Is Approximately 1/3 of the Comparable Antibody Level Against the Original Corona Virus   Benzinga
06:55AM EST  NRx : Scientific Evidence Shows BriLife Vaccine May Produce Effective Levels Of Neutralizing Antibody Against Omicron   RTTNews
06:51AM EST  NRx Announces Publication of Initial Findings of BriLife(r) Vaccine-produced   PR Newswire
Jan 26, 2022
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
07:33AM EST  NRx Pharmaceuticals (NRXP) Wednesday said it received a first safety report for its investigational Covid-19 drug ZYESAMI from a Southwestern hospital.   RTTNews
06:54AM EST  NRx Receives Initial Report Of Patient Safety And Survival From Right To Try Use Of ZYESAMI   RTTNews
06:51AM EST  NRx Receives Initial Report of Patient Safety and Survival from Right to Try   PR Newswire
Jan 23, 2022
10:57AM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Jan 18, 2022
06:18PM EST  Pomerantz Law Firm Announces the Filing of a Class Action Against   GlobeNewswire Inc
08:50AM EST  NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments   Benzinga
06:49AM EST  NRx Pharmaceuticals Announces Expansion Of ZYESAMI US Expanded Access And Right To Try Programs For Patients With COVID-19 Respiratory Failure Who Have Exhausted All Approved Treatments   Benzinga
06:48AM EST  NRx Pharmaceuticals Announces Expansion of ZYESAMI   GlobeNewswire Inc
Jan 14, 2022
02:36PM EST  NRx Responds To Relief's Allegations Of Jan. 14, 2022; Says Neither Co, Nor Jonathon Javitt Accused Current Relief Management Or Board Of Criminal Past   Benzinga
02:34PM EST  NRx Responds to Reliefs Allegations of January   GlobeNewswire Inc
Jan 13, 2022
11:47AM EST  The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact   Benzinga
11:45AM EST  NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights   Benzinga
Jan 12, 2022
05:49PM EST  NRx Pharma Reports Filing Of Counterclaim Against Former Collab Partner, Relief Therapeutics   Benzinga
05:48PM EST  NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration   PR Newswire
Jan 11, 2022
07:57AM EST  NRx Announces Planned Study Investigating BriLife Booster Vaccine Against Omicron Variant   Benzinga
07:55AM EST  NRx Announces Planned Study Investigating   GlobeNewswire Inc
Jan 7, 2022
05:50PM EST  -- New details of clinical trial for BriLife to be discussed during company update presentation at the H.C. Wainwright BioConnect Virtual Conference -- Company presentation time changed to 9 AM EST on Monday, January 10, 2022   GlobeNewswire Inc
01:02PM EST  NRx Pharma Chair, CEO To Present Co. Business Update At HC Wainwright BioConnect Conference Jan. 10, 2022 At 7 a.m. EST   Benzinga
06:48AM EST  NRx Pharmaceuticals Chairman and Chief Executive   GlobeNewswire Inc
Jan 5, 2022
08:20AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets   Benzinga
07:31AM EST  NRx Seeks Emergency Approval For ZYESAMI To Treat Patients   RTTNews
06:52AM EST  NRx Submits EUA Application To FDA For ZYESAMI To Treat Patients At Immediate Risk Of Death From COVID-19   RTTNews
06:49AM EST  NRx Pharmaceuticals Submits Emergency Use Authorization Application To FDA For ZYESAMI To Treat Patients At Immediate Risk Of Death From COVID-19 Despite Treatment With Remdesivir And Other Approved Therapies   Benzinga
06:48AM EST  and Drug Administration for ZYESAMI(r) (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies   PR Newswire
Jan 3, 2022
07:32AM EST  NRx Pharmaceuticals (NRXP) said that it has filed a provisional composition of matter patent application with the US Patent and Trademark Office entitled "Stable, Buffer-free Compositions of Vasoactive Intestinal Peptide (VIP)."   RTTNews
07:19AM EST  NRx Pharma Files Provisional Patent For Stable Compositions Of Aviptadil Suitable For Human Use   RTTNews
07:17AM EST  NRx Pharmaceuticals Files Provisional Patent For Stable Compositions Of Aviptadil Suitable For Human Use   Benzinga
07:17AM EST  NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of   PR Newswire
Dec 29, 2021
07:16AM EST  NRx Pharma Files Breakthrough Therapy Designation Request   RTTNews
07:00AM EST  NRx Files Breakthrough Therapy Designation Request For ZYESAMI In Patients At Immediate Risk Of Death From COVID-19   RTTNews
06:49AM EST  NRx Pharmaceuticals Files Breakthrough Therapy Designation Request For ZYESAMI In Patients At Immediate Risk Of Death From COVID-19 Despite Treatment With Remdesivir And Other Approved Therapies   Benzinga
06:48AM EST  ZYESAMI(r) (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies   PR Newswire
Dec 15, 2021
08:03AM EST  The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO   Benzinga
06:51AM EST  NRx Pharmaceuticals Added to the Nasdaq Biotech Index   Benzinga
06:48AM EST  -- The Nasdaq Biotechnology Index (NBI) is a market index comprised of Nasdaq listed Biotechnology and Pharmaceutical companies   GlobeNewswire Inc
Dec 14, 2021
06:53AM EST  NRx Pharmaceuticals Announces New Safety Report For ZYESAMI; Says After Review Of More Than 348 Enrolled Patients In ACTIV-3b Critical Care Study, No New Safety Concerns Identified By Independent Data Safety Monitoring Board   Benzinga
06:48AM EST  -- After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients   GlobeNewswire Inc
Dec 9, 2021
09:22AM EST  -- NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMI -- Hungary to Serve as First European Nation for the Registrational Phase 2b/3 BriLife COVID Vaccine Trial   GlobeNewswire Inc
Dec 6, 2021
09:16AM EST  NRx Announces Completion Of Data Safety Meeting For Phase 2 Trial Of BriLife Vaccine, Phase 2b/3 Registration Trial To Begin in Nation Of Georgia, Israel, European Union, And Other Regions   Benzinga
09:07AM EST  -- Independent Data Safety Monitoring Board has completed review of BriLife phase 2 trial at low, medium, and high doses, with a formal report expected imminently -- NRx has obtained advice from European Medicines Authority and World Health Organization on phase 2b/3 registration trial protocol -- More than 10 countries have reached out to express interest in participation   GlobeNewswire Inc
Nov 30, 2021
04:21PM EST  Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher   Benzinga
04:11PM EST  Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide   Benzinga
Nov 29, 2021
06:32AM EST  NRx Pharmaceuticals Identifies Significantly Higher Likelihood Of Surviving And Recovering From Critical COVID-19 In ZYESAMI Treated Patients Previously Administered Remdesivir   Benzinga
06:31AM EST  NRx Pharmaceuticals Identifies Significantly Higher Likelihood of   GlobeNewswire Inc
Nov 26, 2021
10:08AM EST  NRx Pharmaceuticals Notes New Data On BriLife COVID-19 Vaccine Effectiveness Against Delta Variant Posted By Israel Institute For Biological Research   Benzinga
10:07AM EST  NRx Pharmaceuticals Notes New Data on BriLife COVID-19   GlobeNewswire Inc
Nov 16, 2021
08:31AM EST  The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment   Benzinga
06:01AM EST  NRX Pharmaceuticals Q3 EPS $(0.40) Down From $(0.15) YoY   Benzinga
05:56AM EST  NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results.   GlobeNewswire Inc
04:06AM EST  Earnings Scheduled For November 16, 2021   Benzinga
Nov 12, 2021
11:47AM EST  NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage, biopharmaceutical company, todayannounced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Companys business at the H.C. Wainwright 7th Annual Israel Virtual Conference.   GlobeNewswire Inc
Nov 11, 2021
07:55AM EST  NRx Pharmaceuticals Receives FDA Review Of ZYESAMI Manufacturing Information; FDA Review Allows for High Volume Production Of ZYESAMI, Shelf Life Of ZYESAMI Now Extended From 62 Days To 150 Days   Benzinga
07:54AM EST  -- US Food and Drug Administration Review Allows for High Volume Production of ZYESAMI (aviptadil) -- Shelf Life of ZYESAMI Now Extended from 62 Days to 150 Days   GlobeNewswire Inc
Nov 9, 2021
12:32PM EST  NRx Pharmaceuticals to Report Third Quarter 2021 Financial and   GlobeNewswire Inc
Nov 5, 2021
09:43AM EDT  The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill   Benzinga
09:38AM EDT  NRx Pharma Reports Initiation Of Senior Level Finance, Business Initiatives With Luxembourg Ministry Of The Economy, BNP Paribas, Vaccine Manufacturing Partners For BriLife COVID-19 Vaccine Production   Benzinga
09:33AM EDT  NRx Pharma Reports FDA Declines Emergency Use Authorization For ZYESAMI For Patients With Critical COVID-19 With Respiratory Failure   Benzinga
06:48AM EDT  with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife(r) COVID-19 Vaccine Production   PR Newswire
Nov 4, 2021
06:08PM EDT  ZYESAMI(r) (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure   PR Newswire
Nov 3, 2021
06:39AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT).   RTTNews
Nov 2, 2021
11:15AM EDT  UPDATE: NRx Pharma Says ZYESAMI Study Was Cleared To Continue Enrollment to Target 640 Patients   Benzinga
11:15AM EDT  UPDATE: NRx Pharma Reports 'After Review of More than 300 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board'   Benzinga
11:15AM EDT  NRx Pharma Highlights New Safety Report For ZYESAMI In National Institutes Of Health-Sponsored ACTIV-3b Critical Care Study In Patients With Life-Threatening COVID-19   Benzinga
11:11AM EDT  (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19   PR Newswire
Oct 21, 2021
04:25PM EDT  NRX Pharmaceuticals Says Entered Into A Shareholder Agreement With Shimshon Hen And David Sepiashvili   Benzinga
Oct 14, 2021
12:54PM EDT  EXCLUSIVE: NRx Pharmaceuticals CEO Jonathan Javitt, On Co.'s Trial Data Of Aviptadil, Says 'The improvement in the test group's overall respiratory distress ratio and cytokine levels add biologic credibility to the positive findings from this study'   Benzinga
10:27AM EDT  Why NRX Pharmaceuticals Stock Is Surging Today   Benzinga
06:50AM EDT  Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure   Benzinga
06:48AM EDT  Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure   PR Newswire
Oct 13, 2021
06:43AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT).   RTTNews
Oct 12, 2021
03:54PM EDT  Why NRX Pharmaceuticals Shares Are Rising   Benzinga
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
07:14AM EDT  NRx Pharma Says Revised Investigational New Drug Module On Manufacturing Of ZYESAMI Submitted To US FDA   RTTNews
06:48AM EDT  NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale   PR Newswire
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
06:30AM EDT  The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT).   RTTNews
Sep 29, 2021
07:21AM EDT  NRx Pharma: Data Safety Monitoring Board Finds No New   RTTNews
06:54AM EDT  NRx Pharma Provides Safety Update On ZYESAMI In ACTIV-3b Critical Care Phase 3 Study   RTTNews
06:50AM EDT  NRx Pharmaceuticals Provides Update On NIH Sponsored ACTIV-3b Critical Care Study; Says Independent Data Safety Monitoring Board 'found no new safety concerns, after reviewing a total of 231 patients, and recommended continued enrollment.'   Benzinga
06:48AM EDT  (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19   PR Newswire
Sep 27, 2021
07:22AM EDT  NRx Pharma Announces Improved Survival At One Year In Highly Comorbid COVID-19 Patients Treated With ZYESAMI   RTTNews
07:09AM EDT  NRx Pharmaceuticals Announces Topline Data At One Year In Highly Comorbid COVID-19 Patients Treated With ZYESAMI (aviptadil)   Benzinga
07:05AM EDT  NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid   PR Newswire
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 13, 2021
04:16PM EDT  IQVIA And NRx Pharmaceuticals Collaborate On Potential Medical Support For Novel COVID-19 Treatment   Benzinga
Sep 8, 2021
07:48AM EDT  NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global   PR Newswire
Sep 7, 2021
06:25AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 6.10 A.M. EDT).   RTTNews
Aug 30, 2021
10:37AM EDT  NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 7 percent on Monday morning after the company announced that Zyesami or aviptadil phase 2b/3 clinical trial demonstrated relief from respiratory distress in critical COVID-19 patients.   RTTNews
08:31AM EDT  NRx Pharmaceuticals (NRXP) said that new finding from its phase 2b/3 trial of Zyesami has demonstrated clinically significant relief from respiratory distress in critical COVID-19. The trial evaluated Zyesami or aviptadil for the treatment of patients with acute Respiratory Failure due to Critical COVID-19.   RTTNews
08:10AM EDT  NRx : Finding From ZYESAMI Phase 2b/3 Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19   RTTNews
08:09AM EDT  NRx Pharmaceuticals Highlights New Finding From ZYESAMI Phase 2b/3 Clinical Trial Demonstrating 'Clinically Significant Relief From Respiratory Distress In Critical COVID-19'   Benzinga
08:07AM EDT  2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19   PR Newswire
Aug 26, 2021
09:50AM EDT  Why NRX Pharmaceuticals Stock Is Trading Higher Today   Benzinga
06:52AM EDT  NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies   Benzinga
06:48AM EDT  NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient   PR Newswire
Aug 24, 2021
06:54AM EDT  NRx Pharma Completes Private Placement For Purchase Of 2.73 Mln Shares   RTTNews
06:48AM EDT  NRx Pharmaceuticals Announces Closing of $30 Million Private Placement   PR Newswire
Aug 23, 2021
09:36AM EDT  NRx Pharma Highlights Reports In Israeli Media Participants In Its BriLife Vaccine Trial Were Notified By Local Health Authorities That They Did Not Need a Third Booster Dose Of The Vaccine 6 Months After Second Dose   Benzinga
09:36AM EDT  NRx Pharma : Participants In High Dose BriLife Investigational Vaccine Trial For COVID-19 Advised Booster Not Necessary   RTTNews
09:34AM EDT  Participants in High Dose BriLife(tm) Investigational Vaccine Trial for   PR Newswire
Aug 19, 2021
09:21AM EDT  NRx Pharma Enters Into Agreements With Investors To Purchase 2.73 Mln Shares Of Common Stock In Private Placement   RTTNews
09:19AM EDT  NRx Pharmaceuticals Announces $30 Million Private Placement   PR Newswire
Aug 18, 2021
11:55AM EDT  NRx Pharmaceuticals Announces Data Safety Monitoring Board For ACTIV-3 Critical Care Study Found No New Safety Concerns In The Trial And Recommended Continued Enrollment   Benzinga
11:54AM EDT  (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19   PR Newswire
Aug 16, 2021
10:01PM EDT  NRx Pharma Q2 Net Loss Widens To $16.0 Mln From $0.1 Mln Prior Year   RTTNews
09:33PM EDT  NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update   PR Newswire
04:04AM EDT  Earnings Scheduled For August 16, 2021   Benzinga
Aug 11, 2021
04:21PM EDT  NRx Pharmaceuticals to Report Second Quarter 2021 Results August   GlobeNewswire Inc
Aug 10, 2021
06:48AM EDT  NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021   PR Newswire
Aug 9, 2021
02:05PM EDT  NRx Pharma Starts Mid-Stage COVID-19 Vaccine Trial In Nation of Georgia   Benzinga
01:18PM EDT  NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife(tm)   PR Newswire
01:18PM EDT  NRx Pharmaceuticals Announces Initiation Of Phase 2b Trial Of BriLife Vaccine For Covid-19 In Nation Of Georgia   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
07:50AM EDT  MannKind Corp. (MNKD) said it has partnered with NRx Pharmaceuticals (NRXP) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI or aviptadil, a synthetic form of human Vasoactive Intestinal Peptide - an endogenous substance produced by the body that helps protect cells against inflammatory conditions.   RTTNews
06:54AM EDT  MannKind Partners With NRx Pharm To Explore Dry Powder Formulation Of ZYESAMI Based On Technosphere Platform   RTTNews
06:50AM EDT  MannKind Corporation And NRx Pharmaceuticals To Evaluate Feasibility Of Formulating A Dry Powder Formulation Of ZYESAMI   Benzinga
06:48AM EDT  NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI(tm)   PR Newswire
06:48AM EDT  MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation   PR Newswire
Jul 27, 2021
12:40PM EDT  NRx Pharma Stock Gains On Emergency Use Nod For Zyesami To Treat COVID-19 Patients In Nation Of Georgia   Benzinga
11:38AM EDT  NRx Pharmaceuticals Announces Emergency Use Authorization Of ZYESAMI In Nation Of Georgia   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 22, 2021
02:42PM EDT  Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher   Benzinga
12:51PM EDT  Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge   Benzinga
11:34AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO   Benzinga
11:10AM EDT  NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 31 percent on Thursday morning after the company announced first successful commercial formulation of Zyesami or aviptadil for intravenous use in COVID-19 patients.   RTTNews
08:18AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO   Benzinga
06:54AM EDT  NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI, Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval   Benzinga
06:53AM EDT  NRx Pharma Unveils First Successful Commercial Formulation For ZYESAMI   RTTNews
06:48AM EDT  ZYESAMI(tm) (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval   PR Newswire
Jul 19, 2021
02:34PM EDT  Mid-Afternoon Market Update: Dow Tumbles 850 Points; Aehr Test Systems Shares Surge   Benzinga
12:09PM EDT  Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher   Benzinga
10:21AM EDT  Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates   Benzinga
08:57AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Jul. 19, 2021: RCL, CELU, CMG, NRXP, RCAT   Benzinga
08:16AM EDT  NRx Pharma Stock Surges As Its COVID-19 Candidate Shows Evidence To Prevent "Cytokine Storm"   Benzinga
06:52AM EDT  NRx Pharma Presents Evidence ZYESAMI Helps Prevent Cytokine Storm In Patients With COVID-19   RTTNews
06:51AM EDT  NRx Pharmaceuticals Presents Evidence ZYESAMI Helps Prevent "Cytokine Storm" In Patients With COVID-19   Benzinga
06:48AM EDT  NRx Pharmaceuticals Presents Evidence ZYESAMI(tm) (aviptadil) Helps Prevent   PR Newswire
Jul 12, 2021
02:42PM EDT  NRX Pharmaceuticals shares were trading higher after the company and Quantum Leap announced they have begun treating COVID-19 patients with ZYESAMI in the I-SPY COVID trial.   Benzinga
12:11PM EDT  NRX Pharmaceuticals Files For Offering Of ~8.76M Shares   Benzinga
11:30AM EDT  NRx Pharma Starts Treating Patients With Inhaled Aviptadil In Collaborative COVID-19 Trial   Benzinga
11:20AM EDT  NRx Pharmaceuticals Announces Partnership With Israel Institute For Biological Research To Complete Development And Commercialization Of BriLife COVID Vaccine   Benzinga
11:20AM EDT  Biological Research to Complete Development and Commercialization of BriLife(tm) COVID Vaccine   PR Newswire
09:30AM EDT  NRx Pharmaceuticals, Inc. (NRXP) and Quantum Leap Healthcare Collaborative have begun treating patients with inhaled ZYESAMI (Aviptadil), in the I-SPY COVID Trial (NCT04488081), a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients.   RTTNews
08:47AM EDT  NRx Pharma And Quantum Leap Announce Treatment Of Severely Ill COVID-19 Patients With ZYESAMI In The I-SPY COVID Trial   RTTNews
08:46AM EDT  NRx Pharmaceuticals And Quantum Leap Have Begun Treating COVID-19 Patients With ZYESAMI (Aviptadil) In I-SPY COVID Trial   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 6, 2021
10:26AM EDT  NRx Pharmaceuticals (NRXP) said Tuesday that it is initiating clinical training of Nation of Georgia ICU physicians, in the use of intravenous ZYESAMI or Aviptadil- acetate for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMI for use in phase 2/3 clinical trials, for patients suffering with COVID-19.   RTTNews
09:23AM EDT  NRx Extends Ongoing Phase 2/3 Trial Of Inhaled ZYESAMI To Georgia For Patients Suffering With COVID-19   RTTNews
09:21AM EDT  Extension of Phase 2/3 Inhaled ZYESAMI(tm) (Aviptadil-acetate) Trial in the Nation of Georgia   PR Newswire
Jun 15, 2021
07:36AM EDT  NRx Pharma Announces Positive Data Results From ZYESAMI Expanded Access Protocol   RTTNews
07:35AM EDT  NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI Expanded Access Protocol   Benzinga
07:34AM EDT  NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI(tm)   PR Newswire
Jun 1, 2021
12:15PM EDT  NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure   Benzinga
07:54AM EDT  Clinical-stage pharmaceutical company NRx Pharmaceuticals, Inc., (NRXP) announced Tuesday positive study results for ZYESAMI (Aviptadil-acetate). The company has filed an application with U.S. Food and Drug Administration requesting Emergency Use Authorization or EUA for ZYESAMI to treat Critically Ill COVID-19 patients suffering with respiratory failure.   RTTNews
06:37AM EDT  NRx Pharma Seeks Emergency Use Approval For ZYESAMI To Treat COVID-19   RTTNews
06:30AM EDT  NRx Pharmaceuticals Files Application With FDA For Emergency Use Authorization Of ZYESAMI In COVID-19   Benzinga
06:28AM EDT  (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure   PR Newswire
May 27, 2021
06:50AM EDT  NRx Pharmaceuticals Names H.R. McMaster To Board   RTTNews
06:49AM EDT  NRx Pharmaceuticals Names General H.R. McMaster to Company's Board of Directors   PR Newswire
May 26, 2021
01:03PM EDT  Clinical-stage pharmaceutical company NRx Pharmaceuticals, Inc., (NRXP) announced on Wednesday, through its Georgia subsidiary, that it signed a master services agreement to conduct Phase 3 clinical trials of COVID-19 drugs and vaccines in the Central Europe and the Caucasus Region. The agreement was signed with Longview, Washington-based Cromos Pharma, LLC.   RTTNews
09:47AM EDT  NRx Pharma To Lead Development Of COVID-19 Medicines And Vaccines In Central Europe   RTTNews
09:32AM EDT  NRx Pharmaceuticals Says To Lead Development Of COVID-19 Medicines And Vaccines In Central Europe, The Caucasus Region In Collaboration With Lugar Institute, Cromos Pharma   Benzinga
09:30AM EDT  Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC